Jobs / United States / Generate Biomedicines INC
Vice President, Head of Immunology and Inflammation Development
Generate Biomedicines INC · 🇺🇸 Remote · Remote
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 14 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 2 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Generate Biomedicines INC
The US Department of Labor certified 14 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 2 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Generate Biomedicines INC →
About the role
The Role: Generate:Biomedicines is seeking an experienced and strategic drug developer and people leader to guide our late-stage Immunology and Inflammation (I&I) programs. Reporting directly to the Chief Medical Officer I&I, this senior business leader will shape integrated development strategies and lead cross-functional teams from late-stage clinical development through regulatory submission and approval. The successful VP, Head of I&I Development candidate will recruit, build, and develop a high-performing team of physicians and scientists, creating clear accountability while enabling strong collaboration across Clinical Operations, Safety, Regulatory, Biometrics, Translational Sciences, and other key functions. They will be accountable for the design and delivery of rigorous late-phase development programs, ensuring scientific and clinical excellence, robust safety oversight, data integrity, and alignment with the company’s broader strategy. The ideal candidate is an MD, MD/PhD, or PhD with significant biopharmaceutical industry experience in immunology and a demonstrated track record of strategic drug development, executional excellence in pivotal trials, and building and leading high-performing teams. Here's how you will contribute: • Leads a high performing Product Strategy Team (PST) comprised of cross-functional leaders accountable for setting the strategy for the late stage I&I programs • Develops high quality, ambitious development plans for aligned with late-stage and corporate objectives and compliant with all relevant regulations • Recruits, mentors and develops a team of late-stage clinicians and scientists • Collaborates with Head of Safety and PV to define risk-benefit profiles • Collaborates with Clinical Operations and CRO to deliver study to timelines and budget • Leads programs through registration development and BLA readiness, ensuring clinical strategy, evidence generation, and execution support successful global regulatory submissions. • Drives development and refinement of Target Product Profiles (TPPs), Target Product Claims, and clinical development strategies • Guide interactions with external stakeholders including KOLs, advisory boards, and CROs • Represent Generate externally at scientific, medical, and regulatory meetings • Provides medical leadership and awareness of evolving external landscape for late-stage clinical trials in respiratory diseases Leadership Responsibilities • Lead, develop, and mentor a high-performing team of physicians and clinical scientists. • Hold teams to high standards for technical and collaborative performance • Build and develop a diverse, high-performing, and inclusive team culture • Promote enterprise thinking and cross-functional alignment with strategic goals • Communicate with clarity, courage, and empathy across all levels of the organization • Foster resilience, adaptability, and informed risk-taking in pursuit of innovation The Ideal Candidate will have: • MD, MD/PhD, or PhD is required. Board certification in Pulmonology, Allergy and Immunology, or Rheumatology is preferred but not required. • 10+ years of drug development experience in the biopharma industry • 4+ years direct people management experience in industry • Deep expertise in global late-stage (Phase III) clinical trials • Prior ex perience leading a cross-functional clinical development team through pivotal development and successful BLA/NDA submission • Demonstrated success in leading pivotal global studies and regulatory interactions • Strong analytical, communication, and cross-functional leadership skills • Proven ability to influence internal and external stakeholders, including investors, investigators, and health authorities Nice to Have (Optional): • Previou